Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19

Massimo Franchini; Claudia Del Fante; Catherine Klersy; Claudia Glingani; Elena Percivalle; Fausto Baldanti; Cesare Perotti

doi:10.1055/s-0040-1713433

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2020; 46(07): 804-806
DOI: 10.1055/s-0040-1713433

Commentary

Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19

Authors

Massimo Franchini

¹Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy
Claudia Del Fante

²Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Catherine Klersy

³Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Claudia Glingani

¹Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy
Elena Percivalle

⁴Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Fausto Baldanti

⁴Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

⁵Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
Cesare Perotti

²Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Abstract

Volltext

Referenzen

References
1 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
2 WHO. Coronavirus disease (COVID-19) outbreak, 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed April 27, 2020
3 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 2020; 92 (05) 479-490
4 Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55 (05) 105955
5 Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020; 14 (02) 126-135
6 Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020; 94: 119-124
7 Cheng Y, Wong R, Soo YO. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 (01) 44-46
8 Arabi YM, Hajeer AH, Luke T. et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22 (09) 1554-1561
9 Chen L, Xiong J, Bao L, Shi Y. Convalescentplasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20 (04) 398-400
10 Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox Sang 2020; (e-pub ahead of print)
11 Wong HK, Lee CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 2020; (e-pub ahead of print)
12 Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020; (e-pub ahead of print)
13 Bloch EM, Shoham S, Casadevall A. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020; 130 (06) 2757-2765
14 Duan K, Liu B, Li C. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117 (17) 9490-9496
15 World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim guidance. Available at: https://www.who.int/publications-detail/clinical-management-of-covid-19 . Accessed June 2, 2020
16 Shen C, Wang Z, Zhao F. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323 (16) 1582-1589
17 Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol 2020; (e-pub ahead of print)
18 Perotti C, Del Fante C, Baldanti F. et al. Plasma from donors recovered from new Corona virus 2019 as therapy for critical patients with COVID-19 (COVID-19 Plasma study). A multicentre study protocol. Intern Emerg Med 2020 [epub ahead of print] doi: 10.1007/s11739-020-02384-2
19 Franchini M, Marano G, Velati C, Pati I, Pupella S, Liumbruno G. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang 2020; (e-pub ahead of print)
20 Franchini M, Farrugia A, Velati C. et al. The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy. Vox Sang 2020; (e-pub ahead of print)
21 Li G, Fan Y, Lai Y. et al. Coronavirus infections and immune responses. J Med Virol 2020; 92 (04) 424-432
22 Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection. J Microbiol Immunol Infect 2020; (e-pub ahead of print)
23 Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci 2020; 16 (10) 1718-1723
24 Wang F, Hou H, Luo Y. et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020; 5 (10) 137799
25 Lindholm PF, Ramsey G, Kwaan AC. Passive immunity for COVID 19–a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost 2020; (e-pub ahead of print)